Japan MHLW budget request rises 3.2%

9 September 2007

Japan's Ministry of Health, Labor and Welfare has increased its fiscal year 2008 budget request to 22,160.4 billion yen ($190.58 billion), a 3.2% rise compared to the initial figure asked for in 2007.

Although the increase includes a real rise of 750.0 billion yen, such as for the pension benefits, the Ministry will reduce this by 220.0 billion yen to 530.0 billion yen, mainly through cutting National Health Insurance drug prices and promoting the use of generic drugs.

With regard to the allocations for pharmaceutical-related policies, 29.5 billion yen will be for promoting the discovery and development of innovative drugs and medical devices, an increase of 4.8 billion yen comared to the initial budget request earlier this year. In addition, 11.3 billion yen will go toward measures to ensure the rapid provision of safe and effective drugs and medical devices, a rise of 600.0 million yen.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight